Ivan Rybár, Rudolf Hyrdel, Jozef Rovenský
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage arthritis. While controlling symptoms and improving quality of life, NSAID use is associated with gastroduodenal injury and risk for symptomatic gastroduodenal ulceration, hemorrhage, and perforation. This requires clinicians to balance the efficacy of NSAIDs against potential risk of serious gastrointestinal events. Identification of risk factors can help guide the optimal approach for arthritis management of individual patients or large populations. This review discuss the main epidemiological, pathophysiological and clinical aspects of NSAID-induced gastropathy including available therapy and prophylaxis.